Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.
Actively Recruiting
Researchers are conducting a prospective, observational study to assess the health of multiple organs in adults with type 2 diabetes who have no history of cardiovascular disease. The goal is to understand if detailed MRI measurements can help predict future clinical events over a 5-year period. Participants include adults diagnosed with type 2 diabetes, especially those diagnosed within the last three years. Participants will undergo no changes to their standard medical care. The study involves two main visits within one month the first includes body measurements and collection of blood and urine samples for routine diabetes checks, and the second involves a multi-organ, multiparametric MRI scan. Data from these visits, along with access to medical records, will be used to monitor disease progression and predict outcomes over 1, 3, and 5 years. Throughout the 5-year study, researchers will collect MRI metrics, clinical outcomes, and lab samples to evaluate diabetes progression. Participants consent to access their hospital and mortality records for event tracking. The primary outcome is the rate of major cardiovascular events three years after the baseline MRI. Secondary outcomes include kidney, eye, liver, cancer, and mortality events assessed at 1, 3, and 5 years. The study requires only a short period of active participation, with long-term follow-up through record review.